A hospital-acquired infection is most commonly spread in a hospital setting. The most common way this is done is through the spread of a contamination from one patient to another. Medical waste products, such as a syringe may aid in spread of contagious bacteria. Once this bacteria is introduced into the body of another patient, the HAI soon begins to multiply within that individual.
The global hospital-acquired disease testing market is expected to be valued at US$ 925.4 million in 2019, and is expected to exhibit a CAGR of 20.0% over the forecast period (2019-2027).
Get Sample Report with Latest Insights @
Rising incidence of hospital-acquired diseases is expected to propel growth of the global hospital-acquired disease testing market over the forecast period. For instance, around 4,650 cases of clostridium difficile (c. diff) Infection were reported in the National Health Service hospitals in England in year 2017, according to the House of Commons Library, UK Parliament.
High prevalence of urinary tract infections is expected to offer lucrative growth opportunities for players in the global hospital-acquired disease testing market. For instance, according to the World Health Organization, 2018, urinary tract infections accounted for 40% of all the hospital acquired infections.
Market: Recent Developments
Major players operating in the global hospital-acquired disease testing market are focused on approval and launch of new products to expand their product portfolio. For instance, in November 2018, the U.S. Food and Drug Administration granted 510K clearance to Biomérieux for BIOFIRE FILMARRAY Pneumonia Panel that aids in lower respiratory tract infection diagnosis.
Major players operating in the global hospital-acquired disease testing market are focused on approval and launch of new products to expand their product portfolio. For instance, in October 2018, GenePOC, a subsidiary of Debiopharm Group, launched GenePOC CDiff assay, a qualitative in-vitro diagnostic test to detect the toxin B (tcdB) gene of toxigenic C. difficile in patients with C. difficile infection.
Get PDF Brochure with Latest Insights @
Covid-19 Impact Analysis:
Emergence of Covid-19 has led to lower focus on other infectious diseases. The pandemic has spread across the world. In Russian Federation, from 3 January 2020 to 6:19pm CEST, 27 September 2021, there have been 7,443,149 confirmed cases of COVID-19 with 204,679 deaths, reported to WHO. According to a study published in September 2021 in Infection Control & Hospital Epidemiology, there was significant increase in the U.S. national standardized infection ratios (SIRs) for MRSA, CLABSI, CAUTI, and VAE in 2020 compared with 2019.
The global hospital-acquired disease testing market is expected to exhibit a CAGR of 20.0% over the forecast period, owing to government initiatives to prevent spread of HAIs. For instance, in November 2019, The Biomedical Advanced Research and Development Authority, a part of the U.S. Department of Health and Human Services, partnered with Inflammatix Inc., a company focused on developing molecular diagnostics for acute infections and sepsis, to support R&D of three rapid diagnostics tests that can read gene expression patterns in immune system to classify bacterial infections from viral infections.
Global Hospital-Acquired Disease Testing Market: Competitive Landscape
Major players operating in the global hospital-acquired disease testing market include, Biomérieux, Cepheid, Cantel Medical Corporation, Diatherix Laboratories, F. Hoffmann-La Roche Ltd., Life Technologies, Luminex Corporation, Meridian Biosciences Inc., Nordion Inc., amd Qiagen GmbH.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027